Novo Nordisk advances obesity candidate to late stage program after weight loss of less than 12% What Novo Nordisk's disappointing trial results mean for the obesity drug market Novo Nordisk presents phase 3 data for next generation amylin cagrilintide, leading to advancement into dedicated clinical programme Novo Nordisk's Bold 3% Gain After Cagrilintide Data
Shopping security
Each payment you make on thelockerguy is secured with strict SSL encryption and PCI DSS data protection protocols